Cogent Biosciences Inc
Weekly Stock Prices Chart
This stock price chart for Cogent Biosciences Inc, symbol COGT, Nasdaq Stock Exchange is updated
weekly.
TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes.
[Add symbol to "MyMenu"]
Daily and Monthly charts are also available for Cogent Biosciences Inc.
Most Recent HeadlinesMNA: Dec 9th, 2024, 00:45Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 22:50Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 21:55Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 21:00Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 20:06Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 19:09Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 18:14Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 17:17Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 16:20Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 15:27Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)
|
